Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Other Non-Current Assets: 2017-2024

Historic Other Non-Current Assets for Cidara Therapeutics (CDTX) over the last 8 years, with Dec 2024 value amounting to $96,000.

  • Cidara Therapeutics' Other Non-Current Assets rose 1798.71% to $23.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.6 million, marking a year-over-year increase of 1798.71%. This contributed to the annual value of $96,000 for FY2024, which is 98.97% down from last year.
  • Per Cidara Therapeutics' latest filing, its Other Non-Current Assets stood at $96,000 for FY2024, which was down 98.97% from $9.3 million recorded in FY2023.
  • Cidara Therapeutics' 5-year Other Non-Current Assets high stood at $9.3 million for FY2023, and its period low was $96,000 during FY2024.
  • Its 3-year average for Other Non-Current Assets is $3.5 million, with a median of $1.1 million in 2022.
  • As far as peak fluctuations go, Cidara Therapeutics' Other Non-Current Assets spiked by 766.60% in 2023, and later plummeted by 98.97% in 2024.
  • Cidara Therapeutics' Other Non-Current Assets (Yearly) stood at $2.0 million in 2020, then increased by 28.18% to $2.6 million in 2021, then slumped by 58.66% to $1.1 million in 2022, then surged by 766.60% to $9.3 million in 2023, then crashed by 98.97% to $96,000 in 2024.